CD8A and breast cancer: Second, this local combinatorial treatment may allow for the use of concurrent systemic therapy, such as chemotherapy plus anti-PD-1/PD-L1 therapy, and potentiate their antitumor efficacy because of ISIM-mediated increases in CD8+ T cell infiltration in mammary tumors, but more importantly distant metastatic lesions.